What is uBriGene Biosciences?
uBriGene Biosciences is dedicated to advancing biologics development, aiming to streamline the journey from initial concept through to commercialization. The company focuses on delivering high-quality products and services designed to optimize both time and cost efficiencies for its clients within the biopharmaceutical industry. This strategic focus positions uBriGene Biosciences as a key player in accelerating the development lifecycle for complex biological therapeutics.
How much funding has uBriGene Biosciences raised?
uBriGene Biosciences has raised a total of $68M across 3 funding rounds:
Series A
$19M
Series B
$29M
Series C
$20M
Series A (2020): $19M, investors not publicly disclosed
Series B (2021): $29M, investors not publicly disclosed
Series C (2023): $20M, investors not publicly disclosed
What's next for uBriGene Biosciences?
With the recent infusion of capital, uBriGene Biosciences is poised for accelerated growth and enhanced operational capabilities. The major strategic investment signals strong market confidence and provides the necessary resources to further innovate and expand its service offerings. This funding will likely be directed towards scaling operations, enhancing research and development initiatives, and potentially broadening its client base. The company's commitment to quality and efficiency suggests a strategic expansion into new markets or the development of advanced technological platforms to support the evolving needs of the biopharmaceutical sector.
See full uBriGene Biosciences company page
